SCHEMBL7254577

SCHEMBL7254577

CCOC(=O)c1n[nH]c(C(=O)OCC)c1C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
KDM4E B2RXH2 4/20 0.47
POLB P06746 1/20 0.46
PDE4D Q08499 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HTT P42858 2/20 0.40
RECQL P46063 1/20 0.40
NR1H2 P55055 1/20 0.39
MEN1 O00255 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
AURKA O14965 1/20 0.37
MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23112307 0.86 MAPT (0.48) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL24229974 0.83 KDM4E (0.46) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL10860621 0.80 KDM4E (0.51) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL7254411 0.78 MAPT (0.63) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL9941259 0.78 KDM4E (0.50) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL10861249 0.78 PDE4D (0.56) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL19253412 0.77 MAPT (0.55) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL1456428 0.77 KDM4E (0.49) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL24229977 0.76 LMNA (0.47) MAPTKDM4EPOLBPDE4DSMN1; SMN2
SCHEMBL23112395 0.75 KDM4E (0.48) MAPTKDM4EPOLBPDE4DSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324865-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US disclosed
EP-3793559-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES Bayer Aktiengesellschaft (DE) 2021-03-24 EP disclosed
CN-112469412-A Substituted dihydropyrazolopyrazine carboxamide derivatives 拜耳公司 2021-03-09 CN disclosed
WO-2003087063-A1 IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324865-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES QDPR, SIRT5, PDXK MAPT 3520/4885KDM4E 2278/4885POLB 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.